The revolutionary gene editing tool CRISPR/Cas9 has reached its height because of its accuracy and easy-to-design. Several gene corrections have been made by scientists in vitro and in vivo. For more information, visit, www.theblackchalk.com

1. Top 10 companies using CRISPR technology
theblackchalk.com/top-10-companies-using-crispr-technology/
The revolutionary gene editing tool CRISPR/Cas9 has reached its height
because of its accuracy and easy-to-design. Several gene corrections have
been made by scientists in vitro and in vivo.
Now, researchers are trying to utilize this ‘molecular whitener ‘ to address
various problems include gene correction, increase the crop yield, enhance
the biofuels production, etc.
There are a few public and private companies have been established. Here,
we presented our top 10 companies using CRISPR technology.
Mammoth Biosciences
Mammoth Biosciences founded by CRISPR expert Jennifer Doudna and
others include Janice Chen and Lucas Harrington from Berkeley, Trevor
Martin and Ashley Tehranchi from Stanford. This life science-based
company is the first ever CRISPR-based detection platform that can
able to sense disease or biomarker with DNA/RNA.
Mammoth Biosciences was led by top investors and includes Mayfield,
NFX, 8VC, AME Cloud, Wireframe, Kairos, and Boom Capital.
1/9

2. Funding size: $23M
Employees: 11-20
Total investors: 12
Website: www.mammoth.bio
Openings: https://mammoth.bio/join-us
Beam Therapeutics
Beam Therapeutics is emerging precision genetic medicines for several
diseases. Co-founded by a well-known CRISPR scientist Feng Zhang and
other scientific developers known for CRISPR/Cas9 gene editing.
Beam Therapeutics are the first company to develop new therapies
using CRISPR base editing method. They have planned to develop a
wide channel of precision genetic medicines that correct point
mutations, write in protective genetic variations, or alter the function of
disease-causing genes.
Funding size: $135M
2/9

3. Employees: 61-70
Total investors: 11
Website: www.beamtx.com
Openings: https://beamtx.com/careers/
Editas Medicine
Editas Medicine is a discovery-phase pharmaceutical-based company in
Cambridge, Massachusetts. They develop therapies based on
CRISPR/Cas9 system. The company was founded in 2013 with funding
from several companies include Third Rock Ventures, Polaris Partners
and Flagship Ventures.
Added to this, funding is also obtained from various CRISPR patents
from the Harvard’s David Liu and George Church, patents from Broad
Institute’s Feng Zhang and patents from Partners Healthcare-MGH’s J.
Keith Joung. Along with Jennifer Doudna, there are four co-founder and
scientific advisory board members.
Funding size: $120M
Employees: 101-200
Total investors: 11
Website:
www.editasmedicine.com
Openings: https://www.editasmedicine.com/community/#careers
Synthego
3/9

4. Synthego is the genome editing-based company. The company’s
automated full stack genome editing technology allows wider access to
CRISPR-based scientific discovery. They also uncover remedies for
various genetic diseases and develop innovative synthetic biology
applications.
Synthego is located in Silicon Valley, Synthego is used by researchers
from the largest global biomedical companies and global biology
institutions to unravel the potential of gene editing.
Funding size: $110M
Employees: 51-200
Total investors: 17
Website: www.synthego.com
Openings: https://www.synthego.com/careers
CRISPR Therapeutics
CRISPR Therapeutics is one of the leading gene-editing companies
dedicated to the advancement of transformative medicines using its
patented CRISPR/Cas9 platform. Their associative group of global
scientists and drug developers is currently working to translate this
technique into human therapeutics in a number of genetic diseases.
Currently, they are collaborating with Vertex Pharmaceuticals and
Bayer AG to expand their range and enable them with distinctive
capabilities. The company is headquartered in Zug, Switzerland and
R&D operations in Cambridge, Massachusetts, USA.
4/9

5. Funding size: $400M
Employees: 101-200
Total investors: 2
Website: www.crisprtx.com
Openings: http://www.crisprtx.com/careers
Interllia Therapeutics
Interllia Therapeutics focuses on the development of patented
therapeutics using CRISPR/Cas9 system. The potential of the
CRISPR/Cas9 technology is the driving force behind Intellia. Their
creators have a common trust that the CRISPR/Cas9 system has the
potential to change medicine by editing genes involved in diseases in
the human body. They are hoping to bring cures to patients who now
have nowhere to receive for help.
5/9

6. Funding size: $700M
Employees: 201-500
Total investors: 9
Website: www.intelliatx.com
Openings: https://www.intelliatx.com/were-in/join-in/
SNIPR Biome
SNIPR Biome is an innovative company that uses CRISPR/Cas9
technology to correct human diseases. They use the technology to
accurately destroy target bacteria, whilst keeping the rest of the
microbial populations intact and unharmed.
SNIPR Biome uses the natural CRISPR-based adaptive immune system
in an engineered manner to fight against target bacteria based on their
specific genomes. Their drugs are next-generation antibiotics
concealing DNA-based CRISPR-Guided Vectors™ (CGV™ Technology)
that cause DNA damage in bacterial genomes.
6/9

7. Funding size: $50M
Employees: 11-50
Total investors: 1
Website: www.sniprbiome.com
Openings: https://www.sniprbiome.com/careers-overview
Caribou Biosciences
Caribou Biosciences is a leading CRISPR/Cas9-based genome editing
companies in the world. They develop method-based solutions for
cellular engineering and analysis-based on the CRISPR-Cas9 platform.
Caribou’s technologies mark a remarkable expansion that permits
researchers to reprogram nearly any part of any genome with
flexibility. Caribou’s tools give transformative capabilities to basic and
applied biological research, agricultural biotechnology, therapeutic
development, and industrial biotechnology.
Funding size: $75M
Employees: 11-50
Total investors: 14
Website: www.cariboubio.com
Openings: https://cariboubio.com/careers
7/9

8. Exonics Therapeutics
Exonics Therapeutics was established in February 2017 to pursue the
research of their founder, Dr. Eric Olson and his research lab at the
University of Texas Southwestern Medical Center (UTSW) to develop
treatments for people with neuromuscular diseases.
In particular, this company uses the adeno-associated virus (AAV)
CRISPR/Cas9 delivery into the target cells. Also, they are identifying and
repair exon mutations to reestablish the production of dystrophin, a
protein that aids soothe and protect muscle fibres.
Funding size: $45M
Employees: 11-50
Total investors: 2
Website: www.exonicstx.com
Openings: http://exonicstx.com/careers/
Horizon Discovery
Horizon Discovery is one of the world-leading gene editing companies
that engineers genetically-modified cells, implementing them in clinical
applications to improve human health.
Horizon’s proprietary gene-editing technology, able to modify almost
any gene sequence, has prepared a catalogue of over 23,000 cells and
in vivo models that summarize the genetic irregularities found in
diseases like cancer. Horizon Discovery serves a different range of
services to customers as well as in the company’s own R&D pipeline.
8/9

9. Funding size: $57M
Employees: 201-500
Total investors: 14
Website: www.horizondiscovery.com
Openings: https://www.horizondiscovery.com/about-us/careers
9/9